摘要
目的 分析及评估使用核苷类似物长期抗病毒治疗的慢性乙型肝炎（CHB）患者肝癌发生情况与乙型肝炎e抗原（HBeAg）表达的相关性.方法 系统性总结进行核苷类似物抗病毒治疗的排除肝癌的CHB患者56例（试验组）的临床资料,均接受抗病毒治疗满5年,同时收集同时期未进行抗病毒治疗的CHB患者56例（对照组）的临床资料,分析影响肝癌发生的各项危险因素.结果 试验组肝癌发生率7.14％（4/56）,对照组肝癌发生率19.64％（11/56）,两组比较差异有统计学意义（P＜0.05）.试验组无肝硬化患者36例中HBeAg（＋）者肝癌发生率0,HBeAg（-）者肝癌发生率1/18,差异有统计学意义（P＜0.05）.结论 CHB患者长期进行核苷类似物抗病毒治疗明显降低了肝癌的发生率,但并不能完全消除肝癌发生的危险,HBeAg（-）仍是无肝硬化CHB患者肝癌发生的危险因素.
Objective To analyze and evaluate the relationship between hepoatocelluar carcinoma incidence and hepatitis B e antigen （HBeAg） expression in choronic hepatitis B （CHB） patients with long-term treatment of nucleoside analogue therapy.Methods The clinical data of 56 CHB patients with long-term treatment of nucleoside analogue therapy except for hepoatocelluar carcinoma （experimental group）were summarized retrospectively,and all patients underwent anti-viral therapy with no less than 5 years.The clinical data of 56 CHB patients without anti-viral therapy in the same period （control group） were collected.The risk factors of hepoatocelluar carcinoma were analyzed.Results The incidence of hepoatocelluar caroinoma was 7.14% （4/56） in experimental group and 19.64% （11/56） in control group,and there was significant difference （P 〈 0.05）.The incidence of hepoatocelluar carcinoma was 0 in patients with positive HBeAg without cirrhosis （36 cases） in experimental group and 1/8 in patients with negative HBeAg without cirrhosis in experimental group,and there was significant difference （P〈 0.05）.Conclusions Long-term treatment of nucleoside analogue therapy can reduce but bot eliminate the hepatocellular carcinoma risk in patients with CHB,especially in those with negative HBeAg.HBeAg negativity is a significant risk factor for the development of hepallerular carcinoma in CHB patients without liver cirrhosis.
出处
《中国医师进修杂志》
2013年第34期20-22,共3页
Chinese Journal of Postgraduates of Medicine
关键词
肝炎
乙型
慢性
核苷类
癌
肝细胞
肝炎
Hepatitis B,chronic
Nucleosides
Carcinoma, hepatocellular
Hepatitis
